Alle Studien
RekrutierungPhase IIInterventionell

Maralixibat for the treatment of intrahepatic cholestasis of pregnancy

Intrahepatic cholestasis of pregnancy (ICP) is a common liver problem affecting thousands of UK pregnancies each year. It causes uncomfortable itching and raises levels of bile acids in the blood, which can sometimes lead to premature birth. Existing treatments do not always give enough relief, so doctors are looking for better options. The METAPHOR clinical trial is testing a medicine called maralixibat. Maralixibat is already used to treat liver problems in children. It works directly in the gut to help clear extra bile acids out of the body, rather than travelling through the bloodstream. Researchers at Imperial College London are testing maralixibat in 28 pregnant women to check its safety, see if it soothes severe itching, and find out whether it lowers bile acid levels until delivery.

Auf einen Blick

Status
Rekrutierung
Phase
Phase II
Sponsor
Imperial College London
Einschreibeziel
28
Starten
23. Aug 2026
Geschätzte Fertigstellung
17 Dec 2027

Worum geht es in dieser Studie?

Intrahepatic cholestasis of pregnancy (ICP) is a liver condition that affects around 5,500 pregnant women in the UK every year. The liver makes substances called bile acids to help digest food. During pregnancy, hormones can slow down the normal flow of these bile acids, causing them to build up in the mother's blood. This can trigger intense itching, which often disturbs sleep, and can also increase the risk of the baby being born early.

While doctors have ways to monitor and treat ICP, current medicines do not work well for everyone. The METAPHOR study is looking at a new treatment called maralixibat. This medicine is already used safely in children with other liver conditions. Researchers hope it can help pregnant women with ICP by binding to bile acids in the digestive system and removing them through the bowel.

Because maralixibat stays mostly in the gut and is barely absorbed into the blood, scientists believe it is unlikely to spread widely through the mother's body or harm the baby. However, this is the first time it is being tested in pregnancy. This study will carefully check how well it works, how safe it is, and whether it can improve comfort and peace of mind during pregnancy.

Wichtige Erkenntnisse

  • The METAPHOR trial is testing a medicine called maralixibat for intrahepatic cholestasis of pregnancy (ICP).
  • ICP causes severe itching and raises bile acid levels in the blood, which can pose risks to the baby.
  • Maralixibat works in the gut to help remove extra bile acids before they build up in the body.
  • The study is open to pregnant women aged 18 to 50 between 20 and 34 weeks of pregnancy.
  • All participants receive the study medicine, and health checks will continue until delivery.

Wer könnte berechtigt sein?

You may be able to join this study if you are a pregnant woman aged between 18 and 50 years old, carrying one baby or twins, and are between 20 and 34 weeks pregnant. You must be receiving your pregnancy care at an NHS hospital running the trial.

To take part, you need a confirmed diagnosis of ICP. This means you have itching that started during your pregnancy with no other obvious cause, and blood tests showing high bile acid levels (19 micromoles per litre or higher).

You will not be able to join if you have certain other ongoing liver conditions. You will also be asked to avoid specific medications during the study, such as certain immune-system medicines or cholesterol drugs called statins. If you take medicines like steroids or certain antidepressants, you must have been on a steady dose for at least 12 weeks.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. I am between 18 and 50 years old.
  2. I am currently between 20 and 34 weeks pregnant (with one baby or twins).
  3. I have been diagnosed with ICP and have unexplained itching in pregnancy.
  4. A recent blood test showed my bile acid level was 19 µmol/L or higher.
  5. I am receiving antenatal care at a participating NHS hospital.
  6. I do not have other chronic liver conditions.
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you take part, you will be given maralixibat to take every day until your baby arrives. You will start on a lower dose, which the research team can adjust if needed. Everyone in this trial receives the real medicine; there is no dummy pill (placebo). Throughout your pregnancy, you will have regular hospital visits alongside your normal antenatal appointments. The team will take blood samples to monitor your bile acid levels and your liver health. You will also be asked to fill in a weekly questionnaire about your itching to track how you are feeling. The study team will stay in touch and monitor you and your baby until birth.

Potenzielle Risiken und Vorteile

Taking part may help lower your bile acid levels and reduce your itching, which could make your pregnancy more comfortable and help protect your baby. However, there is no guarantee you will personally benefit. The most common known side effect of maralixibat is diarrhoea or loose stools, which is why treatment starts with a low dose. Because this medicine has not been given to pregnant women before, there may also be risks that are not yet known. Taking part is completely voluntary, and you can change your mind and leave the study at any point without it affecting your standard NHS maternity care.

Standorte (1)

  • -
    Unbestätigt
    -, England

Häufige Fragen

Will taking this medicine pass into my bloodstream and reach my baby?

Maralixibat works locally inside your gut and is barely absorbed into your blood. Researchers expect that very little, if any, will travel to your baby, though safety is being carefully checked in this trial.

Is there a placebo (dummy medicine) in this trial?

No. All 28 women who join this study will receive the active study medicine, maralixibat.

How long will I take the study medicine?

You will take the medicine every day from when you join the study until you give birth to your baby.

What happens if I experience side effects like diarrhoea?

The study team will start you on a low dose to reduce this risk. If you do get tummy upsets, let the study doctors know so they can review your dose or help manage your symptoms.

Kann ich die Studie verlassen, wenn ich meine Meinung ändere?

Yes. You are free to stop taking part at any time. Your decision will not change the quality of your regular NHS pregnancy care in any way.

Wie Sie mehr erfahren können

Amalia Ndoutoumou

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "Maralixibat for the treatment of intrahepatic cholestasis of… wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.